Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting

Core Points - Galapagos NV has published its annual report for the financial year 2024 and announced its Annual Shareholders' Meeting (AGM) scheduled for April 29, 2025 [1][2] - The AGM agenda includes the appointment of Mr. Oleg Nodelman as Non-Executive Non-Independent Director and the confirmation of the statutory auditor for sustainability reporting [3] - The proposed separation of Galapagos into two publicly traded entities will not be discussed at the AGM, with an Extraordinary Shareholders' Meeting expected to be convened in mid-2025 regarding this matter [4] Company Overview - Galapagos is a biotechnology company operating in Europe and the U.S., focused on transforming patient outcomes through innovative science and technology [6] - The company aims to address high unmet medical needs and has developed a deep pipeline of best-in-class medicines, including a decentralized cell therapy manufacturing platform [6] - Galapagos is committed to anticipating future healthcare needs and ensuring that its innovations reach those who require them most [6]